AMPAR inhibition lowers S1P in human blood and improves murine autoimmune neuroinflammation by blocking T cell egress from lymph nodes., PMID:40498853
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective., PMID:40481170
Relationship between autoimmunity and COPD: an investigation based on proteomic profiling and antinuclear antibody screening., PMID:40329569
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells., PMID:40277931
ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage., PMID:40266369
A real-world study on tezepelumab effectiveness in severe asthma focusing on small airway dysfunction., PMID:40147569
Exploratory analyses of leukocyte responses in hospitalized patients treated with ozanimod following a severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection., PMID:40025871
Drug Development in Inflammatory Bowel Diseases: What Is Next?, PMID:40006003
Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE., PMID:39919901
Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer., PMID:39835329
An overview of small-molecule agents for the treatment of psoriasis., PMID:39832444
Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS., PMID:39819099
Lab-on-the-Needles: A Microneedle Patch-Based Mobile Unit for Highly Sensitive Ex Vivo and In Vivo Detection of Protein Biomarkers., PMID:39763125
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments., PMID:39755026
Roles of macrophages in lupus nephritis., PMID:39611168
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab., PMID:39582359
Sphingosine-1-phosphate alleviates Sjögren's syndrome-like symptoms via inducing autophagy and regulating status of Treg cells in NOD mice., PMID:39510034
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases., PMID:39387155
Sphingosine-1-phosphate receptor type 4 is critically involved in the regulation of peritoneal B-1 cell trafficking and distribution in vivo., PMID:39344245
Sphingosine-1-Phosphate Receptor 4 links neutrophils and early local inflammation to lymphocyte recruitment into the draining lymph node to facilitate robust germinal center formation., PMID:39188715
[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis]., PMID:39093141
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study., PMID:38991170
Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis., PMID:38901377
FTY720 ameliorates experimental MPO-ANCA-associated vasculitis by regulating fatty acid oxidation via the neutrophil PPARα-CPT1a pathway., PMID:38837706
Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells., PMID:38730731
Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis-A Real-World Scenario., PMID:38543930
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer., PMID:38542328
[Comorbidities in multiple sclerosis and their influence on the choice of treatment]., PMID:38482703
Sphingosine-1-phosphate promotes osteogenesis by stimulating osteoblast growth and neovascularization in a vascular endothelial growth factor-dependent manner., PMID:38477738
Assessment of the Effects of Sphingosine Kinase 1/Sphingosine-1-Phosphate on Microangiogenesis at Rat Myofascial Trigger Points Using Contrast-Enhanced Ultrasonography., PMID:38371480
Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review., PMID:38343058
The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma., PMID:38339325
Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis., PMID:38289534
Expression of sphingosine-1-phosphate receptor 1 in neuroinflammation of canine brains., PMID:38182045
Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy., PMID:38096793
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy., PMID:38069222
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod., PMID:37942812
Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders., PMID:37657307
Abnormal Lymphatic Sphingosine-1-Phosphate Signaling Aggravates Lymphatic Dysfunction and Tissue Inflammation., PMID:37609838
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies., PMID:37589743
Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2)., PMID:37431628
Abnormal lymphatic S1P signaling aggravates lymphatic dysfunction and tissue inflammation., PMID:37398237
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?, PMID:37247488
The link between the sphingolipid rheostat and obstructive sleep apnea., PMID:37169814
Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis., PMID:37149155
Lysophospholipids and their producing enzymes: Their pathological roles and potential as pathological biomarkers., PMID:37061204
Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases., PMID:36858313
Blocking SphK/S1P/S1PR1 axis signaling pathway alleviates remifentanil-induced hyperalgesia in rats., PMID:36801239
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators., PMID:36608538
Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis., PMID:36535106
For research use only. Not for human or drug use.
